Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.infigratinibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of infigratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.irinotecanMonitor Closely (1)fluvoxamine will increase the level or effect of irinotecan by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.irinotecan liposomalMonitor Closely (1)fluvoxamine will increase the level or effect of irinotecan liposomal by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.isavuconazonium sulfateMonitor Closely (1)fluvoxamine will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isocarboxazidContraindicated (1)fluvoxamine and isocarboxazid both increase serotonin levels. Contraindicated.isofluraneSerious - Use Alternative (1)isoflurane and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.isoniazidMonitor Closely (1)fluvoxamine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.itraconazoleMonitor Closely (1)itraconazole and fluvoxamine both increase QTc interval. Use Caution/Monitor.ivacaftorMonitor Closely (1)fluvoxamine will increase the level or effect of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce ivacaftor dose if coadministered with CYP3A4 inhibitors; see ivacaftor prescribing information for precise dosage informationivosidenibMonitor Closely (1)fluvoxamine will increase the level or effect of ivosidenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase ivosidenib plasma concentrations, thus increasing risk of QTc prolongation; monitor for increased risk of QTc interval prolongationixabepiloneMonitor Closely (1)fluvoxamine will increase the level or effect of ixabepilone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketamineMonitor Closely (1)fluvoxamine will increase the level or effect of ketamine by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor.ketoconazoleMonitor Closely (1)fluvoxamine and ketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.ketoprofenMonitor Closely (1)fluvoxamine, ketoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.ketorolacMonitor Closely (1)fluvoxamine, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.ketorolac intranasalMonitor Closely (1)fluvoxamine, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.L-tryptophanMonitor Closely (1)fluvoxamine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lamotrigineMonitor Closely (1)lamotrigine increases toxicity of fluvoxamine by serotonin levels. Modify Therapy/Monitor Closely. psychomotor impairment may be enhanced.lansoprazoleMonitor Closely (1)fluvoxamine will increase the level or effect of lansoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.lapatinibMonitor Closely (1)fluvoxamine and lapatinib both increase QTc interval. Use Caution/Monitor.lasmiditanMonitor Closely (1)fluvoxamine and lasmiditan both increase serotonin levels. Use Caution/Monitor.lefamulinMonitor Closely (1)fluvoxamine will increase the level or effect of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for adverse effects if lefamulin is coadministered with moderate CYP3A inhibitors.lemborexantMonitor Closely (2)fluvoxamine, lemborexant. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. May have additive effect with other CNS depressants; dose adjustment may be necessary. fluvoxamine will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration of lemborexant with moderate or strong CYP3A4 inhibitorsleniolisibSerious - Use Alternative (1)leniolisib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid leniolisib with CYP1A2 substrates that have a narrow therapeutic indexlevamlodipineMonitor Closely (1)fluvoxamine will increase the level or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. May requre amlodipine dose reduction; monitor for symptoms of hypotension and edema when amlodipine is coadminitered with CYP3A4 inhibitors to determine need for those adjustmentlevofloxacinMonitor Closely (1)fluvoxamine and levofloxacin both increase QTc interval. Use Caution/Monitor.levoketoconazoleMonitor Closely (1)fluvoxamine and levoketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.levomilnacipranSerious - Use Alternative (1)fluvoxamine and levomilnacipran both increase serotonin levels. Avoid or Use Alternate Drug.lidocaineSerious - Use Alternative (1)fluvoxamine and lidocaine both increase serotonin levels. Avoid or Use Alternate Drug.linezolidSerious - Use Alternative (1)fluvoxamine and linezolid both increase serotonin levels. Avoid or Use Alternate Drug.lisdexamfetamineMonitor Closely (1)fluvoxamine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).lithiumMonitor Closely (2)lithium and fluvoxamine both increase QTc interval. Use Caution/Monitor. fluvoxamine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lofepramineMonitor Closely (1)fluvoxamine and lofepramine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and lofepramine both decrease serotonin levels. Avoid or Use Alternate Drug.lomitapideMonitor Closely (1)fluvoxamine will increase the level or effect of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/daylonafarnibContraindicated (1)fluvoxamine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated. lonapegsomatropinMonitor Closely (1)lonapegsomatropin will decrease the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Limited published data indicate that growth hormone treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. Caution with sensitive CYP substrateslopinavirMonitor Closely (1)fluvoxamine will increase the level or effect of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.loratadineMonitor Closely (1)fluvoxamine will increase the level or effect of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lorcaserinMonitor Closely (1)lorcaserin will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.lornoxicamMonitor Closely (1)fluvoxamine, lornoxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.lovastatinSerious - Use Alternative (1)fluvoxamine will increase the level or effect of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.lsdMonitor Closely (1)fluvoxamine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lumateperoneMonitor Closely (1)fluvoxamine will increase the level or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce lumateperone dose to 21 mg/day if coadministered with moderate CYP3A4 inhibitors.lumefantrineMonitor Closely (1)fluvoxamine and lumefantrine both increase QTc interval. Modify Therapy/Monitor Closely.lurasidoneMonitor Closely (1)fluvoxamine, lurasidone. Either increases toxicity of the other by sedation. Use Caution/Monitor. Monitor for increased adverse effects and toxicity.lurbinectedinSerious - Use Alternative (1)fluvoxamine will increase the level or effect of lurbinectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.maprotilineMonitor Closely (1)fluvoxamine and maprotiline both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.maravirocMonitor Closely (1)fluvoxamine will increase the level or effect of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.mavacamtenContraindicated (1)fluvoxamine will increase the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. Monitor Closely (1)fluvoxamine will increase the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. meclofenamateMonitor Closely (1)fluvoxamine, meclofenamate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.mefenamic acidMonitor Closely (1)fluvoxamine, mefenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.melatoninSerious - Use Alternative (1)fluvoxamine will increase the level or effect of melatonin by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of melatonin with strong CYP1A2 inhibitorsmeloxicamMonitor Closely (1)fluvoxamine, meloxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.meperidineSerious - Use Alternative (1)fluvoxamine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.metforminMonitor Closely (1)fluvoxamine increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor.methadoneMonitor Closely (1)fluvoxamine and methadone both increase QTc interval. Use Caution/Monitor.methylene blueSerious - Use Alternative (1)fluvoxamine increases toxicity of methylene blue by serotonin levels. Avoid or Use Alternate Drug.methylphenidate transdermalMonitor Closely (1)methylphenidate transdermal will increase the level or effect of fluvoxamine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. metoclopramideSerious - Use Alternative (1)fluvoxamine and metoclopramide both increase serotonin levels. Avoid or Use Alternate Drug. Additive effects: Increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactionsmetoclopramide intranasalSerious - Use Alternative (1)fluvoxamine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.mexiletineSerious - Use Alternative (1)fluvoxamine will increase the level or effect of mexiletine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.midazolamMonitor Closely (1)fluvoxamine will increase the level or effect of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase risk of hypoventilation, airway obstruction, or apnea and may contribute to profound and/or prolonged drug effectmidazolam intranasalMonitor Closely (1)fluvoxamine will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May increase risk of hypoventilation, airway obstruction, or apnea and may contribute to profound and/or prolonged drug effectmilnacipranSerious - Use Alternative (1)fluvoxamine and milnacipran both increase serotonin levels. Avoid or Use Alternate Drug.mirabegronMonitor Closely (1)mirabegron will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapineMonitor Closely (1)fluvoxamine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)mirtazapine and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.mobocertinibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use of moderate CYP3A4 inhibitor unavoidable, reduce mobocertinib dose by ~50% (eg, 160 to 80 mg); closely monitor QTc interval.morphineMonitor Closely (1)fluvoxamine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.moxifloxacinMonitor Closely (1)fluvoxamine and moxifloxacin both increase QTc interval. Modify Therapy/Monitor Closely.nabumetoneMonitor Closely (1)fluvoxamine, nabumetone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.naldemedineMonitor Closely (1)fluvoxamine will increase the level or effect of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for potential adverse effectsnaproxenMonitor Closely (1)fluvoxamine, naproxen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.naratriptanMonitor Closely (1)fluvoxamine and naratriptan both increase serotonin levels. Modify Therapy/Monitor Closely.nateglinideMonitor Closely (1)fluvoxamine will increase the level or effect of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.nefazodoneSerious - Use Alternative (1)fluvoxamine and nefazodone both increase serotonin levels. Avoid or Use Alternate Drug.nelfinavirMonitor Closely (1)fluvoxamine will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.neratinibSerious - Use Alternative (1)fluvoxamine will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.netupitant/palonosetronSerious - Use Alternative (1)fluvoxamine increases toxicity of netupitant/palonosetron by serotonin levels. Avoid or Use Alternate Drug.nicardipineMonitor Closely (1)fluvoxamine will increase the level or effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nifedipineMonitor Closely (1)fluvoxamine will increase the level or effect of nifedipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibMonitor Closely (1)fluvoxamine will increase the level or effect of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nimodipineMonitor Closely (1)fluvoxamine will increase the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nisoldipineMonitor Closely (1)fluvoxamine will increase the level or effect of nisoldipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nitrendipineMonitor Closely (1)fluvoxamine will increase the level or effect of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.norgestrelMonitor Closely (1)fluvoxamine will increase the level or effect of norgestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong or moderate CYP3A4 inhibitors may increase systemic concentration of norgestrel, which may increase risk for adverse effects nortriptylineMonitor Closely (1)fluvoxamine and nortriptyline both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.octreotideMonitor Closely (1)fluvoxamine and octreotide both increase QTc interval. Modify Therapy/Monitor Closely.octreotide (Antidote)Monitor Closely (1)fluvoxamine and octreotide (Antidote) both increase QTc interval. Modify Therapy/Monitor Closely.ofloxacinMonitor Closely (1)fluvoxamine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineSerious - Use Alternative (2)fluvoxamine will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. olanzapine and fluvoxamine both increase